Semaglutide in medical therapy
The present invention relates to semaglutide for use in weight management.
1. A method for reducing body weight of a subject in need thereof, comprising administering semaglutide subcutaneously to the subject in an amount of about 2.4 mg weekly.
2. The method according to claim 1 , wherein the semaglutide is administered once weekly.
3. The method according to claim 1 , wherein the subject is overweight.
4. The method according to claim 1 , wherein the subject suffers from obesity.
5. The method according to claim 1 , wherein the subject has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, dyslipidemia, sleep apnoea, and urine incontinence.
6. The method according to claim 5 , wherein the subject has type 2 diabetes mellitus.
7. A method for reducing body weight of a subject in need thereof, comprising administering semaglutide subcutaneously to the subject in an amount of 2.4 mg once weekly.
8. The method according to claim 7 , wherein the subject is overweight.
9. The method according to claim 8 , wherein the subject has type 2 diabetes mellitus.
10. The method according to claim 7 , wherein the subject is suffering from obesity.
11. The method according to claim 10 , wherein the subject has type 2 diabetes mellitus.
12. The method according to claim 7 , wherein the subject has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, dyslipidemia, sleep apnea, and urine incontinence.
13. The method according to claim 1 , wherein the subject is overweight and has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, and dyslipidemia.
14. The method according to claim 7 , wherein the subject is overweight and has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, and dyslipidemia.